Key result
Intranasal Ang-1 treatment prevented OVA-induced eosinophilic lung infiltration, attenuated inflammatory cytokines, and reversed the increase in tissue resistance and elastance in an asthma model.
Why the study?
Does intranasal Ang-1 treatment prevent airway inflammation and hyperreactivity in a mouse model of asthma?
Does intranasal Ang-1 treatment prevent airway inflammation and hyperreactivity in a mouse model of asthma?
Intranasal administration of Ang-1 exerts protective anti-inflammatory and functional effects in a murine model of asthma, suggesting potential therapeutic value.
Supports Ang-1 evaluation in asthma models; leaves open translation to human disease and requires clinical trials.
No takes yet. Share an insight, caveat, or question.
Simoes et al. (2008) studied Asthma (animal model). Intranasal Ang-1 treatment vs. No Ang-1 treatment (implied) was evaluated on Histologic, biochemical, and functional changes (eosinophilic lung infiltration, cytokine levels, tissue resistance and elastance). Intranasal Ang-1 treatment prevented OVA-induced eosinophilic lung infiltration, attenuated inflammatory cytokines, and reversed the increase in tissue resistance and elastance in an asthma model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: